Document is current
Any future updates will be listed below
-
Authors
Brazel, Danielle
Nagasaka, Misako
- License Information
-
More Information
Article History
Received: 6 September 2023
Accepted: 8 October 2023
First Online: 25 October 2023
Declarations
:
: COI disclosure: This manuscript did not receive any funding. There are no direct conflicts of interest to disclose. Dr Brazel has no potential conflicts to disclose. Dr Nagasaka has received consulting fees from Caris Life Sciences, honoraria from AstraZeneca, Daiichi Sankyo, Novartis, Lilly, Pfizer, EMD Serono, Genentech, Mirati, Takeda, Janssen, Blueprint Medicine, Regeneron and travel support from AnHeart Therapeutics.
: this report did not meet criteria for IRB approval.
